A fast screening procedure for ketamine and metabolites in urine samples with tandem mass spectrometry

Journal of Analytical Toxicology

Volumn 34, Issue 3, 2010, Pages 149-154

  Lin, Huei R ^a   Lin, Hsiu L ^a   Lee, Shu F ^b   Liu, Chiareiy ^b   Lua, Ahai C ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b Ministry of Health and Welfare   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID ETHYL ESTER; DEHYDRONORKETAMINE; KETAMINE; KETAMINE D4; NORKETAMINE D4; UNCLASSIFIED DRUG; DRUG DERIVATIVE; NORKETAMINE;

ACCURACY; ARTICLE; CONCENTRATION (PARAMETERS); ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACTION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GAS CHROMATOGRAPHY; MASS SPECTROMETRY; SCREENING TEST; TANDEM MASS SPECTROMETRY; URINALYSIS; ADDICTION; CALIBRATION; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LABORATORY DIAGNOSIS; MASS FRAGMENTOGRAPHY; METABOLISM; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE; URINE;

CALIBRATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE REACTIONS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; KETAMINE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; TANDEM MASS SPECTROMETRY;

EID: 77957101462     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/34.3.149     Document Type: Article

References (33)

1. E.F. Domino, P. Chodoff, and G. Corssen. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin. Pharmacol. Ther. 6: 279-291 (1965).
2. G.E. Morgan, Jr. and M.R. Mikhail. Clinical Anesthesiology, 2nd ed. Appleton-Lange, Stamford, CT, 1996, pp 141-143.
3. K.L. Jansen. A review of the nonmedical use of ketamine: use, users and consequences. J. Psychoactive Drugs 32: 419-433 (2000).
4. K.L. Jansen. Transcendental explanations and near death experience. Lancet 337: 244 (1991).
5. S.F. Chuang, S.C. Wu, W.I. Tsay, J.H. Li, R.H. Liu, J.T. Liu, T.C. Lee, Y.T. Yang, and M.P. Sun. Analysis of MDMA and ketamine sample seizures in Taiwan. Taiwan J. Public Health (Taipei) 24: 264-273 (2005).
6. A.C. Lua, H.R. Lin, Y.T. Tseng, A.R. Hu, and P.C. Yeh. Profiles of urine samples from participants at rave party in Taiwan: prevalence of ketamine and MDMA abuse. Forensic Sci. Int. 136: 47- 51 (2003).
7. H.S. Leong, N.L. Tan, C.P. Lui, and T.K. Lee. Evaluation of ke-tamine abuse using hair analysis: concentration trends in a Singapore population. J. Anal. Toxicol. 29: 314-318 (2005)
8. M.E. Mackesy-Amiti, M. Fendrich, and T.P. Johnson. Prevalence of recent illicit substance use and reporting bias among MSM and other urban males. Addict. Behav. 33: 1055-1060 (2008).
9. J.A. Clements and W.S. Nimmo. Pharmacokinetics and analgesic effect of ketamine in man. Br. J. Anaesth. 53: 27-30 (1981).
10. B.R. Lalonde and H.R. Wallage. Postmortem blood ketamine distribution in two fatalities. J. Anal. Toxicol. 28: 71-74 (2004).
11. S.H. Peyton, A.T. Couch, and R.O. Bost. Tissue distribution of ketamine: two case reports. J. Anal. Toxicol. 12: 268-269 (1988).
12. H.R. Lin and A.C. Lua. Detection of acid-labile conjugates of ketamine and its metabolites in urine samples collected from pub participants. J. Anal. Toxicol. 28: 181-186 (2004).
13. H.R. Lin and A.C. Lua. Simultaneous determination of amphetamines and ketamines in urine by gas chromatography/mass spectrometry. Rapid Comm. Mass Spectrom. 20: 1724-1730 (2006).
14. K.A. Moore, J. Sklerov, B. Levine, and A.J. Jacobs. Urine concentrations of ketamine and norketamine following illegal consumption. J. Anal. Toxicol. 25: 583-588 (2001).
15. Department of Health and Human Services. Substance Abuse and Mental Services Administration. Mandatory Guidelines and proposed revisions to mandatory for federal workplace drug testing programs. Fed. Regist. 69: 19644-19673 (2004).
16. M.H. Hung, R.H. Liu, Y.L. Chen, and S.L. Rhodes. Correlation of drug-testing results-immunoassay versus gas chromatography- mass spectrometry. Forensic Sci. Rev. 18: 9-41 (2006).
17. M.H. Huang, M.Y. Wu, C.H. Wu, J.L.Tsai, H.H. Lee, and R.H. Liu. Performance characteristics of ELISAs for monitoring ketamine exposure. Clin. Chim. Acta 379: 59-65 (2007).
18. P.S. Cheng, C.Y. Fu, C.H. Lee, C. Liu, and C.S. Chien. GC-MS quantification of ketamine, norketamine, and dehydronorke-tamine in urine specimens and comparative study using ELISA as the preliminary test methodology. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852: 443-449 (2007).
19. A.C. Lua and H.R. Lin. A rapid and sensitive ESI-MS screening procedure for ketamine and norketamine in urine samples. J. Anal. Toxicol. 28: 680-684 (2004).
20. D.H. Chace, D.S. Millington, N. Terada, S.G. Kahler, C.R. Roe, and L.F. Hofman. Rapid diagnosis of phenylketonuira by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin. Chem. 39: 66-71(1993).
21. D.H. Chace, S.L. Hillman, D.S. Millington, S.G. Kahler, B.W. Adam, and H.L. Levy. Rapid diagnosis of homocystinuira and other hypermthioninemias from newborn's blood spots by tandem mass spectreometry. Clin. Chem. 42: 349-355 (1996).
22. D.H. Chace, J.E. Sherwin, S.L. Hillman, F. Lorey, and G.G. Cunningham. Use of phenylalanine-to-tyrosine ratio determined by tandem mass spectrometry to improve newborn screening for phenylketonuria of early discharge specimens collected in the first 24 hours. Clin. Chem. 44: 2405-2409 (1998).
23. L. Sweetman. Newborn screening by tandem mass spectrometry (MS/MS). Clin. Chem. 42: 345-346 (1996).
24. H.K. Nordgren and O. Beck. Direct screening of urine for MDMA and MDA by liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 27: 15-19 (2003).
25. E. Gustavsson, M. Andersson, N. Stephanson, and O. Back. Validation of direct injection electrospray LC-MS/MS for confirmation of opiates in urine drug testing. J. Mass Spectrom. 42: 881- 889 (2007).
26. J. Zweigenbaum, K. Heinig, S. Steinborner,T. Wachs, and J. Henion. High-throughput bioanalytical LC/MS/MS determination of ben-zodiazepines in human urine: 1000 samples per 12 hours. Anal. Chem. 71: 2294-2300 (1999).
27. W. Weinmann and M. Svoboda. Fast screening for drugs of abuse by solid-phase extraction combined with flow-injection ionspraytandem mass spectrometry. J. Anal. Toxicol. 22: 319-328 (1998).
28. E.K. Shultz. Analytical goals and clinical interpretation of laboratory procedures. In Tietz Textbook of Clinical Chemistry, C.A. Burtis and E.R. Ashwood, Eds. W.B. Saunders, Philadelphia, PA, 1994, pp 485-507.
29. R.H. Liu. Evaluation of common immunoassay kits for effective workplace drug testing. In Handbook of Workplace Drug Testing, R.H. Liu and B.A. Goldberger, Eds. AACC Press, Washington, D.C., 1995, pp 67-129.
30. B.K. Matuszewski, M.L. Constanzer, and C.M. Chavez-Eng. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 75: 3019- 3030 (2003).
31. S.E. Lankenau and M.C. Clatts. Patterns of polydrug use among ketamine injectors in New York City. Subst. Use Misuse 40: 1381- 1397 (2005).
32. C.J. Morgan, L. Muetzelfeldt, and H.V. Curran. Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 104: 77-87 (2009).
33. D.M. Bush. The U.S. Mandatory guidelines for federal workplace drug testing programs: current status and future considerations. Forensic Sci. Int. 174: 111-119 (2008).